Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Apr;16(2):141-150.
doi: 10.1007/s11904-019-00437-6.

Scaling-up PrEP Delivery in Sub-Saharan Africa: What Can We Learn from the Scale-up of ART?

Gabrielle O'Malley  1 , Gena Barnabee  2 , Kenneth Mugwanya  2
Affiliations
Review

Scaling-up PrEP Delivery in Sub-Saharan Africa: What Can We Learn from the Scale-up of ART?

Gabrielle O'Malley et al. Curr HIV/AIDS Rep. 2019 Apr.

Erratum in

Abstract

Purpose of review: Clinical trials have found that PrEP is highly effective in reducing risk of HIV acquisition across types of exposure, gender, PrEP regimens, and dosing schemes. Evidence is urgently needed to inform scale-up of PrEP to meet the ambitious WHO/UNAIDS prevention target of 3,000,000 individuals on PrEP by 2020.

Recent findings: Successful models of delivering HIV services at scale evolved from years of formal research and programmatic evidence. These efforts produced lessons-learned relevant for scaling-up PrEP delivery, including the importance of streamlining laboratory tests, expanding prescription and management authority, differentiating medication access points, and reducing stigma and barriers of parental consent for PrEP uptake. Further research is especially needed in areas differentiating PrEP from ART delivery, including repeat HIV testing to ensure HIV negative status and defining and measuring prevention-effective adherence. Evidence from 15 years of ART scale-up could immediately inform a public health approach to PrEP delivery.

Keywords: Anagogical reasoning; HIV/AIDS; PrEP implementation; Pre-exposure prophylaxis (PrEP); Scaling-up; Sub-Saharan Africa.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

The authors declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

    1. Fauci AS, Eisinger RW. PEPFAR — 15 Years and Counting the Lives Saved. N Engl J Med. 2018;378(4):314–316. - PubMed
    1. Bendavid E. Past and Future Performance: PEPFAR in the Landscape of Foreign Aid for Health. Current HIV/AIDS reports. 2016;13(5):256–262. - PMC - PubMed
    1. Weller I. Delivery of Antiretroviral Therapy in Sub-Saharan Africa. Clin Infect Dis. 2006, 43(6):777–8. 10.1086/507113. - PubMed
    1. Baggaley R, Hensen B, Ajose O, Grabbe KL, Wong VJ, Schilsky A, et al. From caution to urgency: the evolution of HIV testing and counselling in Africa. Bull World Health Organ. 2012;90(9):652–68b. - PMC - PubMed
    1. McCoy D, Chopra M, Loewenson R, Aitken J-M, Ngulube T, Muula A, et al. Expanding Access to Antiretroviral Therapy in Sub-Saharan Africa: Avoiding the Pitfalls and Dangers, Capitalizing on the Opportunities. Am J Public Health. 2005;95(1):18–22. - PMC - PubMed

Substances